Onyx Pharma's (ONXX) Kyprolis 'Killin It'

According to a recent survey by analysts at Baird, Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) is seeing strong initial penetration of multiple myeloma drug Kyprolis in label and off-label use. Commenting on the survey, Baird analyst Christopher J. Raymond said the survey indicates Kyprolis is "just killin’ it".

"Just three months post-launch, Kyprolis has already become the dominant third-line player with 61% of respondents using it in their most preferred regimens," said Raymond. "Despite its third-line-only label, Kyprolis has already captured 11% second-line physician share, used about half the time in combination with dexamethasone."

The Baird survey showed half the doctors surveyed have already prescribed Kyprolis and it was prescribed in 13 percent of all multiple myeloma patients.

Baird has an Outperform rating on Onyx Pharmaceuticals with a price target of $99.00.

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals (NASDAQ: ONXX) click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $77.28 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Marvell (MRVL) PT Raised to $225 at TD Cowen
• WaterBridge Infrastructure (WBI) PT Raised to $40 at Raymond James
• B.Riley Starts Weave Communications Inc (WEAV) at Buy